Ginkgo Bioworks Holdings, Inc. (DNA) Financial Statements
Industry: Biological Products, (No Diagnostic Substances)
In fiscal 2025, Ginkgo Bioworks reported revenue of $170.2M, down 25.1% from $227.0M the year before. Net income was -$312.8M (a -183.8% net margin), or -$5.64 per diluted share. Gross margin was 100.0% and operating margin was -185.3%. Operating activities generated -$171.1M of cash, leaving -$178.7M of free cash flow. At fiscal year end, Ginkgo Bioworks held $1.12B in total assets against $611.1M in total liabilities, including $167.2M of cash and equivalents.
Open the full interactive Ginkgo Bioworks financials → Quarterly statements, key ratios, valuation history and price charts.
Ginkgo Bioworks Key Stats
| Share Price | $11.76 |
|---|---|
| Market Cap | $730.2M |
| Revenue YoY Growth | -25.1% |
| 52-Week Range | $5.48 – $15.83 |
| Shares Outstanding | 62.1 million (basic, 2026 Q2) |
Ginkgo Bioworks Income Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $313.8M | $477.7M | $251.5M | $227.0M | $170.2M |
| Cost of Goods Sold | $20.0M | $20.6M | $7.5M | $0 | $0 |
| Gross Profit | $293.8M | $457.1M | $244.0M | $227.0M | $170.2M |
| Operating Income | -$1.83B | -$2.21B | -$864.4M | -$559.8M | -$315.3M |
| Pre-Tax Income | -$1.84B | -$2.12B | -$892.9M | -$547.5M | -$313.6M |
| Income Tax | -$1.5M | -$15.0M | -$71,000 | -$479,000 | -$837,000 |
| Net Income | -$1.83B | -$2.10B | -$892.9M | -$547.0M | -$312.8M |
| Diluted EPS | -$55.60 | -$50.00 | -$18.40 | -$10.54 | -$5.64 |
Ginkgo Bioworks Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $38.8M | $33.4M | $19.5M | $20.2M |
| Net Income | -$80.8M | -$80.8M | -$82.6M | -$46.7M |
| Diluted EPS | -$1.45 | -$1.46 | — | — |
Ginkgo Bioworks Balance Sheet
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Cash & Equivalents | $1.55B | $1.32B | $944.1M | $561.6M | $167.2M |
| Current Assets | $1.72B | $1.45B | $1.00B | $602.7M | $471.8M |
| Total Assets | $2.07B | $2.54B | $1.67B | $1.38B | $1.12B |
| Current Liabilities | $134.8M | $173.0M | $163.9M | $107.3M | $96.0M |
| Total Liabilities | $503.6M | $803.0M | $568.2M | $661.4M | $611.1M |
| Shareholders' Equity | $1.51B | $1.74B | $1.10B | $716.1M | $508.6M |
Ginkgo Bioworks Cash Flow Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Cash From Operations | -$253.8M | -$252.2M | -$295.5M | -$319.6M | -$171.1M |
| Cash From Investing | -$73.3M | -$67.4M | -$80.7M | -$62.2M | -$240.3M |
| Cash From Financing | $1.53B | $95.3M | -$3.2M | -$1.7M | $17.8M |
| Free Cash Flow | -$310.3M | -$304.5M | -$336.3M | -$382.1M | -$178.7M |
Figures from Ginkgo Bioworks' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Ginkgo Bioworks financials page for every line item.
Ginkgo Bioworks Company Profile
| Ticker | DNA |
|---|---|
| Exchange | NYSE |
| Industry | Biological Products, (No Diagnostic Substances) |
| Headquarters | Boston, Massachusetts |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Accelerated filer |
| SEC CIK | 0001830214 |
Frequently Asked Questions
What was Ginkgo Bioworks' revenue in fiscal 2025?
Ginkgo Bioworks (DNA) reported revenue of $170.2M for fiscal 2025.
What is Ginkgo Bioworks' annual revenue history?
Ginkgo Bioworks' annual revenue by fiscal year: 2021: $313.8M; 2022: $477.7M; 2023: $251.5M; 2024: $227.0M; 2025: $170.2M.
What was Ginkgo Bioworks' net income in fiscal 2025?
Ginkgo Bioworks reported net income of -$312.8M for fiscal 2025.
What was Ginkgo Bioworks' earnings per share (EPS) in fiscal 2025?
Ginkgo Bioworks' diluted EPS was -$5.64 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Ginkgo Bioworks generate in fiscal 2025?
Ginkgo Bioworks generated -$178.7M of free cash flow in fiscal 2025.
What was Ginkgo Bioworks' revenue last quarter?
In its most recent reported quarter (2026 Q2), Ginkgo Bioworks reported revenue of $20.2M.
How many shares of Ginkgo Bioworks are outstanding?
Ginkgo Bioworks reported a weighted average of 62.1 million basic shares outstanding in 2026 Q2.
What is Ginkgo Bioworks' market cap?
Based on its latest closing price, Ginkgo Bioworks (DNA) has a market capitalization of about $730.2M.
When does Ginkgo Bioworks' fiscal year end?
Ginkgo Bioworks' fiscal year end, as registered with the SEC, is December 31.
Where is Ginkgo Bioworks headquartered?
Ginkgo Bioworks lists its business address in Boston, Massachusetts in its SEC filings.
Ginkgo Bioworks Competitors & Similar Companies
See all 136 Biological Products, (No Diagnostic Substances) companies →